β3-adrenoceptor stimulation of perivascular adipocytes leads to increased fat cell-derived nitric oxide and vascular relaxation in small arteries by Bussey, CE et al.
3­adrenoceptor stimulation ofβ  
perivascular adipocytes leads to increased 
fat cell­derived nitric oxide and vascular 
relaxation in small arteries
Bussey, CE, Withers, SB, Saxton, SN, Bodagh, N, Aldous, RG and Heagerty, AM
http://dx.doi.org/10.1111/bph.14433
Title 3­adrenoceptor stimulation of perivascular adipocytes leads to increased β
fat cell­derived nitric oxide and vascular relaxation in small arteries
Authors Bussey, CE, Withers, SB, Saxton, SN, Bodagh, N, Aldous, RG and 
Heagerty, AM
Type Article
URL This version is available at: http://usir.salford.ac.uk/id/eprint/48520/
Published Date 2018
USIR is a digital collection of the research output of the University of Salford. Where copyright 
permits, full text material held in the repository is made freely available online and can be read, 
downloaded and copied for non­commercial private study or research purposes. Please check the 
manuscript for any further copyright restrictions.
For more information, including our policy and submission procedure, please
contact the Repository Team at: usir@salford.ac.uk.
RESEARCH PAPER
β3-Adrenoceptor stimulation of perivascular
adipocytes leads to increased fat cell-derived
NO and vascular relaxation in small arteries
Correspondence Professor Anthony M Heagerty, Institute of Cardiovascular Sciences, Core Technology Facility (3rd ﬂoor), 46 Grafton
Street, Manchester M13 9NT, UK. E-mail: tony.heagerty@manchester.ac.uk
Received 16 May 2017; Revised 4 May 2018; Accepted 19 June 2018
Charlotte E Bussey1 , Sarah B Withers1,2 , Sophie N Saxton1 , Neil Bodagh1 , Robert G Aldous1 and
Anthony M Heagerty1
1Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK, and 2Environment and Life Sciences, University of Salford, Salford, UK
BACKGROUND AND PURPOSE
In response to noradrenaline, healthy perivascular adipose tissue (PVAT) exerts an anticontractile effect on adjacent small arterial
tissue. Organ bath solution transfer experiments have demonstrated the release of PVAT-derived relaxing factors that mediate this
function. The present studies were designed to investigate the mechanism responsible for the noradrenaline-induced PVAT
anticontractile effect.
EXPERIMENTAL APPROACH
In vitro rat small arterial contractile function was assessed using wire myography in the presence and absence of PVAT and the
effects of sympathomimetic stimulation on the PVAT environment explored using Western blotting and assays of organ bath
buffer.
KEY RESULTS
PVAT elicited an anticontractile effect in response to noradrenaline but not phenylephrine stimulation. In arteries surrounded by
intact PVAT, the β3-adrenoceptor agonist, CL-316243, reduced the vasoconstrictor effect of phenylephrine but not noradrena-
line. Kv7 channel inhibition using XE 991 reversed the noradrenaline-induced anticontractile effect in exogenously applied PVAT
studies. Adrenergic stimulation of PVAT with noradrenaline and CL-316243, but not phenylephrine, was associated with in-
creased adipocyte-derived NO production, and the contractile response to noradrenaline was augmented following incubation of
exogenous PVAT with L-NMMA. PVAT from eNOS/mice had no anticontractile effect. Assays of adipocyte cAMP demonstrated
an increase with noradrenaline stimulation implicating Gαs signalling in this process.
CONCLUSIONS AND IMPLICATIONS
We have shown that adipocyte-located β3-adrenoceptor stimulation leads to activation of Gαs signalling pathways with increased
cAMP and the release of adipocyte-derived NO. This process is dependent upon Kv7 channel function. We conclude that
adipocyte-derived NO plays a central role in anticontractile activity when rodent PVAT is stimulated by noradrenaline.
Abbreviations
eNOS, endothelial NOS; KPSS, high potassium physiological salt solution; L-NMMA, NG-monomethyl-L-arginine; nNOS,
neuronal NOS; PDRF, PVAT-derived relaxing factor; PSS, physiological salt solution; PVAT, perivascular adipose tissue; XE
991, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone dihydrochloride
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Introduction
Perivascular adipose tissue (PVAT) surrounds virtually all
blood vessels and exerts an anticontractile effect in response
to various vasoconstrictor agonists (Gao et al., 2007;
Greenstein et al., 2009). The mechanisms by which PVAT ex-
erts this effect are the subject of intense investigations, and
what is clear already from organ bath studies is that adipo-
cytes release transferable relaxing factor(s) (Lohn et al.,
2002; Greenstein et al., 2009). However, the precise identity
of these is unclear.
Recent evidence has indicated that β3-adrenoceptors
may be involved in the release of PVAT-derived relaxing
factors (PDRFs) provoked by sympathomimetic
hormones: Weston et al. (2013) demonstrated that the
speciﬁc β3-agonist, CL-316243, induced endothelium-
independent but PVAT-dependent myocyte hyperpolariza-
tion in rat mesenteric artery via the opening of potassium
BKCa (KCa1.1) channels.
Vascular smooth muscle cell potassium channels are key
regulators of membrane potential, with increased or de-
creased activity resulting in hyperpolarization or depolariza-
tion, respectively, meaning that they act as ‘off switches’ in
excitable cells and occupy a central position in the regulation
of vascular tone (Ghatta et al., 2006). Myocyte membrane po-
tential is hyperpolarized in the presence of PVAT, and sub-
stantial evidence points towards a role of potassium
channels in the anticontractile mechanism. Pharmacological
investigations have led to the identiﬁcation of several potas-
sium channel candidates including Kv7 (Fésüs et al., 2007;
Schleifenbaum et al., 2010) and BKCa (Gao et al., 2005; Lynch
et al., 2013), which appear to undergo differential activation
depending on the vascular bed and species investigated. Col-
lectively, these studies indicate the emerging importance of
PVAT, which appears to exert its anticontractile effect
through a variety of complex pathways that may be activated
in parallel in response to different agonists.
Therefore, the present studies were designed to investigate
the mechanisms responsible for the noradrenaline
(NA)-induced PVAT anticontractile effect. We report that
β3-adrenoceptor stimulation of adipocytes leads to Gαs signal-
ling, a rise in cAMP andKv7 channel activation. ThePDRF isNO.
Methods
Group sizes
For all experiments, the group size is provided within the
ﬁgure legends. For all experiments, the number of animals is
reported. Assays for cAMP and NO were performed in dupli-
cate and an average for each animal used for calculation of
mean data.
Randomization
All rats used in this study were healthy adult male Sprague
Dawley rats bred at Charles River, UK. Rats were randomly
assigned to a numbered cage upon delivery from Charles
River, and the animals were used when they reached an ap-
propriate size (250–300 g). The pharmacological protocol to
be used in each myograph bath was determined prior to
mounting the vessels.
Blinding
Experimental blinding was not used for this study as there
was one core experimenter responsible for dissection, experi-
mental protocols and analysis. In order to limit experimental
bias, data analysis was not performed until experimental data
sets were complete. Duplicate data from a minimum of ﬁve
separate animals were required for all experimental protocols
described.
Normalization
Contractile responses are expressed as mean percentages of
KPSS constriction ± SEM consistent with previously pub-
lished data (Greenstein et al., 2009; Withers et al., 2011). This
allowed for comparison in contractile changes independent
of vessel size.
Validity of animal model
Male Sprague Dawley rats are a well-established model for the
investigation of PVAT function and vascular contractility
(Greenstein et al., 2009; Aghamohammadzadeh et al., 2013).
The eNOS-deﬁcient (eNOS/) mouse model is well pub-
lished and commercially available. This model was chosen
to conﬁrm the role of eNOS in our proposed mechanism.
We have previously shown comparable response of mouse
and rat mesenteric arteries to adrenergic stimulation (Withers
et al., 2011). Myography protocols detailed below have been
validated within our laboratory for rat, mouse and human tis-
sues (Greenstein et al., 2009). Antibodies which were selective
for rat antigens were chosen for immunohistochemistry and
Western blot studies.
Ethical statement
Experiments involving the use of animals were performed in
accord with the UK Animals (Scientiﬁc Procedures) Act 1986
under the authority of a valid project licence. Animal studies
are reported in compliance with the ARRIVE guidelines
(Kilkenny et al., 2010; McGrath and Lilley, 2015). The experi-
ments were approved by The University of Manchester
Ethical Review Process. All work was carried out in accor-
dance with the Declaration of Helsinki.
Animals
Healthy male Sprague Dawley rats (250–300 g; Charles River,
Harlow, Hertfordshire, UK) were killed by CO2 inhalation with
death conﬁrmed by permanent cessation of the circulation by
severing the diaphragm. The mesenteric bed was immediately
removed and placed in ice-cold physiological salt solution
(PSS inmmol·L1: 119 NaCl, 4.7 KCl, 1.17MgSO4, 25 NaHCO3,
1.17 KH2PO4, 0.03 K2 EDTA, 5.5 glucose and 1.6 CaCl2).
Male eNOS-deﬁcient (eNOS/) mice were kindly pro-
vided by Dr Elizabeth Cottrell (Manchester, UK). eNOS/
mice were bred in-house at the University of Manchester
and used at 12-week-old. As a control for eNOS/ mice,
age-matched male C57BL6/j mice were purchased from
Envigo, Belton, Leicestershire, UK. Mice were killed as de-
scribed above. Mesenteric artery samples were obtained and
studied as described below.
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Wire myography
Small mesenteric arteries (internal diameter: 200–300 μm)
both with and without PVAT were dissected and mounted
on two 40 μm wires in a wire myograph (Danish MyoTech,
Aarhus, Denmark, Denmark). The vessels were gassed (95%
air/5% CO2) and maintained in PSS at 37°C for 30 min before
wall tension and diameter were normalized using a standard-
ized procedure (Mulvany and Halpern, 1977). Isometric ten-
sion was continuously recorded (Chart 5, v5.5, AD
Instruments, Oxford, Oxfordshire, UK). Vessels were chal-
lenged with 60 mmol·L1 high potassium PSS (KPSS in
mmol·L1: 63.7 NaCl, 60 KCl, 1.17 MgSO4, 25 NaHCO3,
1.17 KH2PO4, 0.03 K2 EDTA, 5.5 glucose and 1.6 CaCl2) to
establish viability, and functional endothelial integrity was
assessed by relaxation to 10 μmol·L1 carbachol following
stable constriction with 10·μmol·L1 noradrenaline.
When investigating the role of the endothelium, endo-
thelium was removed by inserting equine hair into the lu-
men. Success in removing endothelium was tested using
10 μmol·L1 carbachol as above.
Pharmacological assessment. Pharmacological protocols
were used to study the mechanisms involved in mediating
the PVAT anticontractile effect. In each case, segments from
the same artery were prepared with and without PVAT and
incubated either with PSS as a vehicle control or PSS
containing the pharmacological tool for 30 min. The role of
β3-adrenoceptor-mediated signalling was evaluated by
incubation of vessels with the β3-adrenoceptor agonist,
CL-316243, or the β3-adrenoceptor antagonist, SR 59230A.
The contribution of NO to PVAT function was assessed by
incubation with the non-speciﬁc NOS inhibitor, NG-
monomethyl-L-arginine (L-NMMA) (Aghamohammadzadeh
et al., 2013), and vinyl-L-NIO, which has been shown to be
selective for neuronal NOS (nNOS) at a concentration of
100 nmol·L1 (Babu and Grifﬁth, 1998). Protocols
investigated the contribution of K+ channels through
incubation with the Kv7 channel inhibitor – XE 991
(Li et al., 2013).
Following incubation with pharmacological tools,
concentration–responses were constructed through the cu-
mulative addition of noradrenaline or phenylephrine to the
myograph bath (1 × 107–3.51 × 105 mol·L1). The use of
these two vasoconstrictor agonists allowed the role of β-
adrenoceptor-mediated signalling to be investigated, as nor-
adrenaline has equal afﬁnity for α and β-adrenoceptors,
whereas phenylephrine has higher afﬁnity for α-
adrenoceptors (Minneman et al., 2015).
Solution transfer experiments. Bioassay experiments were
used to study the release of relaxing factors from PVAT
(Lohn et al., 2002; Gao et al., 2007; Greenstein et al., 2009).
PVAT with and without its adjacent artery was used as a
donor, whereas arteries stripped of PVAT were used as
recipients. Both the PVAT and recipient arteries were
stimulated with 30 μmol·L1 noradrenaline, and once a
stable constriction had developed, solutions were removed
from both baths and transferred from the bath containing
the donor PVAT to the recipient artery without PVAT. The
change in tension in the recipient artery was recorded. In
order to investigate the contribution of external calcium to
the anticontractile mechanism, donor PVAT with and
without arteries was stimulated in PSS with (1.6 mmol·L1)
and without calcium. In experiments where PVAT was
incubated in calcium-free PSS, the calcium concentration of
the solution was restored prior to addition to the recipient
artery.
Exogenous PVAT experiments. Concentration–responses to
noradrenaline were also constructed in vessels devoid of
PVAT but with PVAT suspended on a wire within the
myograph bath (exogenous PVAT) to enable examination of
the release of relaxing factors from PVAT in response to
different vasoconstrictor agonists. In some experiments,
exogenous PVAT was incubated with various
pharmacological tools for 30 min before the return of PVAT
to the myograph bath to enable further investigation of
PVAT mechanisms. Exogenous PVAT was incubated with
forskolin to examine the effects of Gαs activation, db-
cAMP to assess the role of cAMP, L-NMMA and vinyl-L-NIO
to explore the role of PVAT-derived NO and XE 991 to
investigate Kv7 activation within PVAT.
Stimulation of PVAT
PVAT samples (~200 mg) were dissected from small mesen-
teric arteries and incubated in HEPES buffer (pH 7.4, in
mmol·L1: 127 NaCl, 5.9 KCl, 1.2 MgSO4, 10 HEPES, 2.4
CaCl2 and 11.8 glucose) in the absence (control) or presence
of noradrenaline (10 μmol·L1) or CL-316243 (10 μmol·L1)
for 30 min at 37°C. The solution surrounding the PVAT (su-
pernatant) was removed, and both tissue and supernatant
were snap frozen in liquid nitrogen and stored separately at
80°C until use.
Western blot analysis
In order to investigate the effects of noradrenaline stimula-
tion on downstream signalling within PVAT, Western blot
analysis was performed on unstimulated and stimulated
PVAT lysate. PVAT samples were homogenized in RIPA buffer
containing protease and phosphatase inhibitors using a
FastPrep-24 5G instrument with lysing matrix 5 tubes. Pro-
tein concentrations were determined using a Bradford assay.
Samples (40 μg of protein) were separated using SDS-PAGE
on a 12% stain-free SDS-PAGE gel (Bio-Rad Laboratories, Wat-
ford, Hertfordshire, UK). Following electrophoresis, samples
were transferred to a low-ﬂuorescence PVDF membrane using
a Trans-Blot Turbo system, and transfer was veriﬁed using
stain-free imaging. Non-speciﬁc binding sites were blocked
with 5% BSA in TBS-Tween (0.1% Tween), followed by over-
night incubation with primary antibody at 4°C. Speciﬁc pri-
mary antibodies against AMPKα (0.27 μg·mL1),
phosphorylated-AMPKα (0.26 μg·mL1), β3-adrenoceptor (5-
μg·mL1) and eNOS (1 μg·mL1) were used. This was followed
by three 10 min washes in TBS-Tween at room temperature
and exposure to secondary antibody (donkey anti-rabbit
HRP, 0.8 μg·mL1) for 1 h at room temperature. Protein reac-
tivity was detected using Clarity Western ECL substrate
chemiluminescent detection reagent and captured digitally
using the ChemiDoc MP imaging system. Stain-free technol-
ogy was used as a normalization tool as it allowed normaliza-
tion to total protein levels through quantiﬁcation of signal
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intensity within the whole sample (Ferguson et al., 2005;
Gurtler et al., 2013). The chemiluminescent signal intensity
of a given protein was normalized to the relative quantiﬁca-
tion of the corresponding intensity of the total protein, and
changes in expression are expressed as the fold increase over
unstimulated controls, assigning a value of 1 to the control.
Data from each replicate were normalized and then averaged
across the replicates, and data are plotted as mean ± SEM.
Immunohistochemistry
PVAT samples were placed in 4% paraformaldehyde for 18 h
and subsequently processed to parafﬁnwax blocks prior to serial
sectioning at 5 μm. Samples were de-waxed using xylene and
rehydrated with ethanol prior to immunostaining for Kv7.4
expression (4 μg·mL1). Heat-induced antigen retrieval was per-
formed followed by blocking of endogenous peroxidase using
3% H2O2 and block of non-speciﬁc binding sites using goat
serum. Sections were incubated with anti-Kv7.4 antibody
overnight, followed by 1 h incubation with Biotin-SP conju-
gated anti-rabbit secondary antibody (1.5 μg·mL1) and detec-
tion using Vectastain ABC complex followed by the addition
of 3,30-diaminobenzidine (DAB) solution to allow visualization
of antibody binding. Images were captured using a colour cam-
era (Leica DFC450) mounted on a microscope (Leica DM5000).
cAMP assay
Following stimulation, PVAT samples were homogenized
using a FastPrep-24 5G instrument with lysing matrix 5 tubes
in ice-cold 0.1 mol·L1 hydrochloric acid at a 1:5 ratio (w.v-1)
to inactivate any PDEs within the sample. Samples were then
centrifuged at 1000 g for 10 min to remove insoluble cellular
debris and neutralized with 1 mol·L1 sodium hydroxide.
Samples were diluted 100-fold in calibrator diluent before in-
tracellular cAMP levels were determined using the competi-
tive enzyme immunoassay cAMP parameter assay kit.
NO levels within PVATsupernatant
NO within PVAT supernatant was converted to detectable ni-
trite by 3 h incubation with nitrate reductase (0.17 U·mL1),
glucose-6-phosphate dehydrogenase (4.17 U·mL1), glucose-
6-phosphate (500 μmol·L1) and NADPH (1.67 μmol·L1)
as described previously (Verdon et al., 1995). A Griess
reagent kit was then used to determine total nitrite
concentration.
Total adiponectin ELISA of PVATsupernatant
Total adiponectin levels in stimulated and non-stimulated
PVAT supernatant samples weremeasured using a commercially
available ELISA kit. Stimulated and unstimulated supernatant
samples were diluted 1:750 in calibrator diluent before the assay
was performed according to the manufacturer’s instructions.
Data and statistical analysis
The data and statistical analysis comply with British Journal
of Pharmacology guidelines (Curtis et al., 2018). GraphPad
Prism (v6, GraphPad Software, USA) was used for all statistical
analyses, and P values< 0.05 were considered statistically sig-
niﬁcant. Contractile responses are expressed as mean per-
centages of KPSS constriction ± SEM, consistent with
previously published data (Greenstein et al., 2009; Withers
et al., 2011), and curves ﬁtted using non-linear regression
analysis. LogEC50 values were calculated from individual
concentration–response curves ﬁtted using non-linear
regression analysis with a sigmoidal function. Data were
analysed using two-way ANOVA following by Bonferroni
post hoc test or by Student’s unpaired or paired t-test
as appropriate.
Materials
Myography. All salts for PSSs, noradrenaline, phenylephrine
and carbachol were purchased from Sigma-Aldrich,
Gillingham, Dorset, UK. All other pharmacological tools were
purchased from R&D Systems, Abingdon, Oxfordshire, UK.
Western blot analysis. General consumables were purchased
from Sigma-Aldrich. Reagents for RIPA buffer were purchased
from Roche Diagnostics, Burgess Hill, West Sussex, UK.
FastPrep-24 5G instrument was purchased from MP
Biomedicals Inc., Santa Ana, California Antibodies used were
as follows: AMPKα (Cell Signaling Technology, Hitchin,
Hertfordshire, Cat #2603 RRID: AB_490795), phosphorylated-
AMPKα (Thr172) (Cell Signaling Technology, Cat #2535, RRID:
AB_331250), β3-adrenoceptor (Novus Biologicals, Abingdon,
Oxfordshire, NBP1-00716, RRID:AB_1502640), eNOS (Santa
Cruz Biotechnology, Dallas, Texas, USA, Cat #sc-654 RRID:
AB_631423) and donkey anti-rabbit HRP (Jackson
ImmunoResearch Laboratories, Ely, Cambridgeshire, Cat #711-
035-152, RRID:AB_10015282). All other Western blot materials
were purchased from Bio-Rad Laboratories.
Immunohistochemistry. General consumables were
purchased from Sigma-Aldrich. Antibodies purchased were
as follows: Kv7.4 (Santa Cruz Biotechnology, Cat #sc-50 417,
RRID: AB_2131729), Biotin-SP conjugated anti-rabbit
secondary antibody (Jackson ImmunoResearch Laboratories,
USA, Cat #711-065-152, RRID: AB_2340593), vectastain ABC
complex and DAB solution (Vector Laboratories,
Peterborough, Cambridgeshire, UK, ABC: Cat #PK-6100,
RRID:AB_2336819 DAB: SK-4100, RRID:AB_2336382).
Assays. All general consumables were purchased from
Sigma-Aldrich. The Griess reagent kit was purchased from
Promega, Chilworth, Southampton, USA. The cAMP,
adiponectin and adipokine assay kits were from R&D
systems, Abingdon, Oxfordshire, USA.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.
org, the common portal for data from the IUPHAR/BPS Guide
to PHARMACOLOGY (Harding et al., 2018), and are perma-
nently achieved in the Concise Guide to PHARMACOLOGY
2017/18 (Alexander et al., 2017a,b,c).
Results
PVAT produces a transferable anticontractile
factor
In endothelium-intact segments of rat mesenteric small arter-
ies, the vasoconstrictor response to noradrenaline (Figure 1A)
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but not phenylephrine was reduced in the presence of
PVAT (Figure 1B). The vasoconstrictor response to nor-
adrenaline was reduced in vessels lacking PVAT with exog-
enous PVAT suspended in the bath (Figure 1A), suggesting
that the anticontractile effect was due to secretion of a sol-
uble factor.
Transfer of solutions from donor PVAT with and without
an artery stimulated with noradrenaline to a recipient artery
lacking PVAT pre-contracted with noradrenaline produced a
signiﬁcant reduction in tension (Figure 1C), conﬁrming that
the anticontractile effect was due to secretion of a soluble fac-
tor. Also, relaxation occurred following incubation of donor
PVAT with and without an artery in calcium-free external
PSS solution and transfer to a recipient artery, indicating that
the anticontractile effect is calcium-independent (Figure 1D).
In endothelium-denuded arteries, the vasoconstrictor re-
sponse to noradrenaline was not reduced by the presence of
PVAT (Figure 1E), conﬁrming that the anticontractile factor
is endothelium-independent.
Adipocyte located β3-adrenergic activation
produces a PVAT-derived anticontractile effect
via Gαs signalling
Western blot analysis indicated the presence of β3-adre-
noceptors within the PVAT of rat mesenteric arteries
Figure 1
The anticontractile capacity of PVAT is produced by secretion of an endothelium-independent soluble factor. The presence of PVAT reduced the
vasoconstrictor response to (A) noradrenaline (n = 18). The contractile response to noradrenaline was also reduced in vessels with exogenous
PVAT (no PVAT vs. exogenous PVAT: P < 0.05, PVAT vs. exogenous PVAT: P = NS, n = 5 and 6 respectively). The presence of PVAT had no effect
on the vasoconstrictor response to (B) phenylephrine (PVAT n = 10, no PVAT n = 12). Both donor PVAT and recipient arteries were stimulated with
30 μmol·L1 noradrenaline prior to transfer. (C) Transfer of solution from donor PVAT to a recipient artery lacking PVAT produced a signiﬁcant
reduction in tension both in the presence (n = 6) and absence (n = 6) of an artery with the PVAT. (D) Transfer of solution from donor PVAT incu-
bated in calcium-free PSS to a recipient artery produced a signiﬁcant reduction in tension in the presence and absence of PVAT (n = 9) and in the
absence of an artery with the PVAT (n = 8). The total external calcium concentration of the recipient bath was kept constant at 1.6 mmol·L1 after
transfer. (E) The anticontractile effect is absent in endothelium-denuded arteries (P = NS, n = 6) Data are expressed as mean ± SEM. *P< 0.05, two-
way ANOVA or paired t-test.
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(Figure 2A); therefore, we investigated the contribution of
β3-adrenoceptor-mediated signalling to the anticontractile ef-
fect. The presence of CL-316243 had no effect on vasocon-
strictor response to noradrenaline (Figure 2B) but reduced
the effect of phenylephrine (Figure 2C), indicating a role for
β3-adrenoceptor activation in mediating the anticontractile
effect of noradrenaline on PVAT. Incubation of vessels with
intact endothelium but lacking PVAT with CL-316243 had
no effect on the vasoconstrictor response to either of the ago-
nists tested (Figure 2D) conﬁrming that the changes observed
are a consequence of β3-adrenoceptor activation within
PVAT. Moreover, the β3-adrenoceptor antagonist, SR
59230A, increased the contractile response to noradrenaline
in vessels with PVAT (Figure 2E) but had no effect on the re-
sponse to phenylephrine (Figure 2F).
Incubation of exogenous PVAT with forskolin had no
effect on the vasoconstrictor response to noradrenaline
(Figure 3A) but reduced the effect of phenylephrine
(Figure 3B). Incubation with db-cAMP had no effect on the
vasoconstrictor response to noradrenaline (Figure 3C) but
reduced the vasoconstrictor response to phenylephrine
(Figure 3D). Intracellular cAMP levels were increased from
Figure 2
β3-adrenoceptor activation contributes to the PVAT anticontractile effect. (A) Representative Western blot indicating expression of
β3-adrenoceptors within rat mesenteric PVAT. Three independent samples were analysed from each rat on one membrane. Incubation of intact
vessels with PVAT with 10 μmol·L1 CL-316243 for 30 min did not alter the response to (B) noradrenaline (n = 5) but enhanced the anticontractile
effect of (C) phenylephrine (n = 5). (D) Incubation of vessels with endothelium but lacking PVAT with 10 μmol·L1 CL-316243 did not alter the
contractile response to phenylephrine (n = 5). Incubation of mesenteric vessels with PVAT with the β3-adrenoceptor antagonist, 1 μmol·L
1 SR
59230A for 30 min potentiated constriction to (E) noradrenaline (n = 7) but had no effect on the contractile response to (F) phenylephrine
(P = NS, n = 7). Data are expressed as mean ± SEM. *P < 0.05, two-way ANOVA.
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250 ± 33 to 467.4 ± 54 pmol·mL1 within PVAT following
stimulation with CL-316243 indicating that β3-adrenoceptor
stimulation involves Gαs signalling (Figure 3E).
Kv7 channel activation contributes to
noradrenaline-mediated anticontractile
capacity
Incubation with the Kv7 inhibitor, XE 991, did not alter
the vasoconstrictor response to noradrenaline in vessels
lacking PVAT (Figure 4A) but potentiated the response to
noradrenaline in vessels with PVAT (Figure 4B). Incuba-
tion of exogenous PVAT with XE 991 prior to placement
within the myograph bath reversed the anticontractile ef-
fect of PVAT (Figure 4C), indicating that Kv7 channel ac-
tivation within PVAT contributes to the noradrenaline-
induced anticontractile capacity. Immunostaining for
Kv7.4 shows Kv7.4 expression within PVAT, the endothe-
lial layer and the adventital layer of the mesenteric artery
(Figure 4D).
Figure 3
Gαs signalling contributes to the noradrenaline-induced PVAT anticontractile effect. Incubation of exogenous PVAT with 1 μmol·L1 forskolin for
30 min prior to placement within the myograph bath had no effect on the vasoconstrictor response to (A) noradrenaline (n = 6) but reduced the
contractile response to (B) phenylephrine (n = 6). Incubation of vessels with PVAT with the cAMP analogue, 10 μmol·L1 db-cAMP had no effect
on constriction to (C) noradrenaline (n = 6) but reduced the vasoconstrictor response to (D) phenylephrine (n = 6). (E) Intracellular cAMP levels
increased following stimulation with 10 μmol·L1 CL-316243 (P < 0.05, n = 6). Data are expressed as mean ± SEM. *P < 0.05, two-way ANOVA.
Vasodilator PVAT function in small arteries
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NO produced by adipocytes plays a key role in
the anticontractile effect
Western blot analysis demonstrated higher eNOS expres-
sion within PVAT than the mesenteric artery (Figure 5A).
Incubation with the NOS inhibitor, L-NMMA, did not alter
the vasoconstrictor response to noradrenaline in vessels
with intact endothelium but lacking PVAT (Figure 5B),
but the vasoconstrictor response was increased in the pres-
ence of PVAT (Figure 5C). Incubation of exogenous PVAT
with L-NMMA prior to placement within the myograph
bath increased the vasoconstrictor response to noradrena-
line (Figure 5D), indicating that PVAT-derived NO may
contribute to the noradrenaline-induced anticontractile ca-
pacity. Incubation with D-NMMA, an inactive enantiomer
of L-NMMA, had no effect on the contractile response of
vessels with PVAT (Figure 5E). Incubation of exogenous
PVAT with nNOS inhibitor vinyl-L-NIO had no effect on
the contractile response (Figure 5F), indicating that eNOS
may be the NOS isoform responsible for NO release from
PVAT. Moreover, the anticontractile effect of PVAT on the
vasoconstrictor response to noradrenaline present in
C57BL6/j mice was absent in eNOS/, mice indicating
that eNOS activation contributes to the release of NO from
PVAT (Figure 6).
β3-Adrenoceptor activation within PVAT does
not alter adiponectin release
Abundant amounts of adiponectin were found to be basally
secreted from PVAT; however, this was unaltered following
stimulation with either noradrenaline or CL-316243
(Figure 7).
Discussion
The present study investigated the mechanisms of the
noradrenaline-induced PVAT anticontractile effect. Themain
ﬁndings were that (i) β3-adrenoceptor-mediated signalling
contributes to the PVAT anticontractile effect; (ii) Kv7 chan-
nel activation within PVAT contributes to release of a PDRF;
and (iii) PVAT-derived NO plays a key role in the
noradrenaline-induced PVAT anticontractile effect.
Consistent with previously published data (Briones et al.,
2005; Garland et al., 2011; Flacco et al., 2013), we demon-
strated no functional role of β3-adrenoceptor-mediated sig-
nalling in the contractile response to noradrenaline in
vessels lacking PVAT. This suggests that the effects observed
in the present study were a consequence of β3-adrenoceptor
activation within the PVAT. This is supported by our previous
Figure 4
Kv7 channel inhibition prevents PVAT anticontractile effect. (A) Incubation of vessels lacking PVAT with the Kv7 inhibitor, XE 991 (10 μmol
.L-1) for
30 min had no effect on the contractile response to noradrenaline (n = 6) but (B) potentiated the contractile response to noradrenaline in vessels
with PVAT (n = 6). (C) Incubation of exogenous PVAT with XE 991 for 30 min prior to addition to the myograph bath produced an increase in the
contractile response in vessels lacking PVAT compared to vessels with control exogenous PVAT (n = 5). (D) Immunostaining showed no staining
when mesenteric bed samples were incubated with rabbit IgG (a) but clear staining within the PVAT, endothelial layer and adventitial layer of the
mesenteric artery when incubated with anti-Kv7.4 antibody (b). Images were obtained at 20x magniﬁcation and scale bar represents 75 μm. Data
are expressed as mean ± SEM. * P < 0.05, one-way ANOVA.
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observations of β3-adrenoceptor expression within mouse
mesenteric PVAT and the effects of adipocyte
β3-adrenoceptor inhibition on vessel tension (Saxton et al.,
2018). In this study, we report a similar β3-adrenoceptor-me-
diated mechanism in rat PVAT and have for the ﬁrst time
identiﬁed PVAT-derived NO as a relaxing factor released upon
β3-adrenoceptor activation.
Adipocyte β3-adrenoceptors are likely activated by sympa-
thetically derived NA. The role of β3-adrenoceptors in cate-
cholamine induced lipolysis has been well characterized
(Bartness et al., 2014; Rebuffe-Scrive, 1991; Robidoux et al.,
2006), and the origin of sympathetic ﬁbres in epididymal
and inguinal fat depots has been extensively studied using vi-
ral transneuronal tract tracers (Bamshad et al., 1998; Song
et al., 2009; Nguyen et al., 2014). Denervation of these fat
depots will lead to a decrease in lipolysis (Rooks et al., 2005;
Foster and Bartness, 2006); however, until recently, the
importance of sympathetic nerves in PVAT was unknown.
Previously, using immunohistochemistry, we have conﬁrmed
the presence of sympathetic nerves in mouse mesenteric
PVAT (Saxton et al., 2018). In addition, we conﬁrmed a func-
tional role for sympathetic nerves in PVAT, as pharmacologi-
cal sympathetic denervation of PVAT abolished the
anticontractile effect. Therefore, it is sympathetically derived
NAwhich activates β3-adrenoceptors, triggering the release of
a relaxing factor.
Dual coupling of β3-adrenoceptors to both Gαs and Gαi
proteins has been reported in 3T3-F440A adipocytes (Soeder
et al., 1999). We highlight an important role of the
β3-adrenoceptor/Gαs/cAMP signalling pathway in the PVAT
anticontractile capacity as β3-adrenoceptor stimulation re-
sulted in cAMP production and incubation with forskolin or
db-cAMP was able to mimic the PVAT anticontractile effect.
This is supported by previous studies showing that
Figure 5
PVAT-derived NO plays a key role. (A) Representative Western blot showing expression of eNOS within PVAT and mesenteric artery (MA). Kidney
(K) was used as a positive control. (B) Incubation of vessels with endothelium but lacking PVAT with either 100 μmol.L-1 or 200 μmol.L-1 L-NMMA
had no effect on the contractile response to noradrenaline (n = 5). (C) Incubation with 100 μmol.L-1 L-NMMA increased the vasoconstrictor
response to noradrenaline in vessels with intact PVAT (n = 6). (D) Incubation of exogenous PVAT with μmol.L-1 L-NMMA for 30 min prior to
suspension within the myograph bath produced an increase in the contractile response in vessels lacking PVAT compared to vessels with control
exogenous PVAT (n = 5). (E) Incubation of vessels with PVAT with D-NMMA did not alter the contractile response to noradrenaline (n = 5).
(F) Incubation of exogenous PVAT with 100 nmol.L-1 Vinyl-L-NIO for 30 min prior to suspension within the myograpth bath had no effect on
contractile response (n = 8). Data are expressed mean ± SEM. * P < 0.05, two-way ANOVA.
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β3-adrenoceptors within cultured adipocytes have a tendency
towards Gαs protein coupling following stimulation with
physiologically relevant catecholamine concentrations
(Soeder et al., 1999; Robidoux et al., 2006).
Our ﬁnding that Kv7 channel inhibition does not alter the
contractile response to noradrenaline in vessels lacking PVAT
was surprising given the key role of Kv7 channels in the regu-
lation of vascular tone (Ng et al., 2011; Chadha et al., 2012).
The majority of studies investigating the effect of Kv7 chan-
nel inhibition on vascular tone has reported increased
myogenicity in the presence of XE 991 rather than investigat-
ing its effect on the arterial response to vasoconstrictor ago-
nists or have demonstrated activation/inhibition of currents
using single-cell electrophysiology in the absence of
spasmogens (Ng et al., 2011; Chadha et al., 2012). Moreover,
we found very little Kv7.4 expression within the arterial me-
dial layer consistent with the absence of a functional role,
and our data are supported by an earlier myograph study
using rat mesenteric artery (Li et al., 2013).
Substantial evidence suggests a role for voltage-gated K+
channels, especially Kv7 in mediating the PVAT
anticontractile effect in resistance arteries (Verlohren et al.,
2004; Schleifenbaum et al., 2010; Zavaritskaya et al., 2013).
For the ﬁrst time, we have shown Kv7.4 expression within
PVAT and that speciﬁc inhibition of Kv7 within PVAT re-
versed the noradrenaline-induced anticontractile effect in
health. This suggests a crucial role for activation of Kv7 lo-
catedwithin PVAT inmediating the release of a relaxing factor
in health. These ﬁndings contradict previous studies that sug-
gested a role for vascular smooth muscle Kv7 channels in me-
diating the anticontractile effect (Fang et al., 2009;
Schleifenbaum et al., 2010; Zavaritskaya et al., 2013). How-
ever, our experimental design allowed speciﬁc inhibition of
Kv7 within PVAT without affecting smooth muscle channels
enabling identiﬁcation of the tissue location of the channels
involved in the PVAT anticontractile effect. Moreover, previ-
ous studies did not investigate Kv7 expression within PVAT,
and on the basis of their results, a role for PVAT Kv7 activation
could not be excluded.
Our data showing a crucial role for Kv7 within the adipo-
cytes are supported by observations of voltage-gated K+ chan-
nels within rat white adipocytes (Ramirez-Ponce et al., 1996)
that can be modulated by noradrenaline and cAMP
(Ramirez-Ponce et al., 1998). Moreover, evidence has emerged
that Kv7 channel activation contributes to the vasodilator re-
sponse induced by β-adrenoceptor agonists through amecha-
nism involving cAMP and PKA, because Kv7 channel
inhibitor linopirdine was able to inhibit relaxations induced
by isoprenaline and forskolin (Chadha et al., 2012), and phos-
phorylation of Kv7.4 by PKA has been reported to shift the ac-
tivation curve leading to enhanced Kv7.4 activity (Chambard
and Ashmore, 2005). Taken together with the observed in-
creased cAMP levels, we suggest that β3-adrenoceptor stimu-
lation within PVAT and subsequent cAMP production leads
to Kv7 activation. This leads to the movement of potassium
out of the adipocyte down its electrochemical gradient and
hyperpolarization that drives calcium entry with subsequent
activation of downstream signalling pathways leading to the
release of NO.
Consistent with earlier work, we were able to show that
PVAT releases a transferable factor (Lohn et al., 2002;
Figure 7
Total adiponectin secretion fromPVAT is not altered by β3-adrenoceptor
activation. Total adiponectin released from PVAT into surrounding
solution was not increased by adrenergic stimulation (n = 6).
Figure 6
The PVAT anticontractile effect is lost in eNOS/ mice. (A) In C57BL6/j mice, the vasoconstrictor response to noradrenaline is reduced in the
presence of PVAT (n = 8). (B) The presence of PVAT had no effect on the vasoconstrictor response to noradrenaline in mesenteric arteries from
eNOS/ mice (n = 8). Data are expressed as mean ± SEM. *P < 0.05, two-way ANOVA.
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Greenstein et al., 2009; Lynch et al., 2013), and we demon-
strate that this factor is adipocyte-derived NO as the
anticontractile effect reversed in the presence of speciﬁc
PVAT NOS inhibition and stimulation with CL-316243, but
not phenylephrine increased NO release from PVAT. Consis-
tent with previous studies, the effects of this factor are
endothelium-independent (Greenstein et al., 2009; Saxton
et al., 2018).
Several studies have demonstrated a link between
β3-adrenoceptor-mediated signalling and NO production by
adipocytes (Canova et al., 2006; Hodis et al., 2011), and recent
electrophysiological studies in non-contracted vessels dem-
onstrated that β3-adrenoceptor-mediated stimulation of
PVAT producedmyocyte hyperpolarization that could be par-
tially reversed by the presence of L-NMMA (Weston et al.,
2013). Moreover, our data support previous ﬁndings in hu-
man s.c. arteries (Greenstein et al., 2009) and mouse
mesenteric arteries (Lynch et al., 2013) where NOS inhibition
was reported to attenuate PVAT function, and we have
recently shown a crucial role for activation of PKG, a down-
stream signalling component in the NO pathway, in the
noradrenaline-induced anticontractile effect in mice
(Withers et al., 2014).
L-NMMA inhibits all three isoforms of NOS (eNOS, nNOS
and iNOS) but may also have non-speciﬁc effects. However,
the lack of effects of the inactive enantiomer, D-NMMA, and
the speciﬁc nNOS inhibitor, vinyl-L-NIO, strongly suggested
that the observed effects of L-NMMA in rat PVAT were a con-
sequence of eNOS inhibition. Endothelial NOS (eNOS) plays
a key role in white adipose tissue metabolism (Sansbury
et al., 2012) and is activated by increased intracellular calcium
(Busse and Mulsch, 1990). Moreover, the PVAT
anticontractile effect was absent in eNOS/ mice, and we
were able to detect greater eNOS expression in PVAT than
Figure 8
Proposed pathway for nitric oxide release by PVAT and how it results in the PVAT anticontractile effect. Noradrenaline (NA) activates β3-
adrenoceptors within PVAT leading to increased cAMP production. This activates Kv7 within PVAT leading to an efﬂux of potassium and subse-
quent hyperpolarisation that drives calcium entry into the adipocyte and activation of endothelial nitric oxide synthase (eNOS) which catalyses
the production of NO from L-arginine (L-Arg). NO is released from PVAT and acts on vascular smooth muscle cells leading to hyperpolarisation
and vasodilatation which opposes vasoconstriction resulting in an anticontractile effect.
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mesenteric artery suggesting that it is the key NOS isoform
catalyzing NO production within PVAT.
Adiponectin promotes NO production within the endo-
thelium (Cheng et al., 2007), and previous studies within
our laboratory have suggested a key role for adiponectin as a
relaxing factor mediating the anticontractile effect in human
s.c. (Greenstein et al., 2009) and mouse mesenteric (Lynch
et al., 2013) arteries and in response to β3-adrenoceptor-medi-
ated stimulation of non-contracted rat mesenteric arteries
(Weston et al., 2013). Also, serum levels of adiponectin were
increased in rats following 7 day infusion of CL-316243
(Zhang et al., 2002), and adiponectin secretion from mouse
mesenteric PVAT is signiﬁcantly reduced when incubated
with SR 59230A (Saxton et al., 2018). Previously,
adiponectin has been shown to induce vasorelaxation in rat
(Greenstein et al., 2009) and mouse (Lynch et al., 2013) mes-
enteric arteries and myocyte hyperpolarization in non-
contracted vessels (Weston et al., 2013). We observed high
basal adiponectin secretion from PVAT; however, no
changes in total adiponectin secretion were observed fol-
lowing stimulation with noradrenaline or CL-316243. This
may be because biologically relevant changes in the ratio
of high MW : low MW isoforms could not be detected
using commercially available ELISA kits (Brochu-Gaudreau
et al., 2010). AMPK is a major downstream target of
adiponectin (Yamauchi et al., 2007), and we show AMPK
phosphorylation in unstimulated PVAT was not altered by
β-adrenoceptor-mediated stimulation, suggesting that
adiponectin may be constitutively released from PVAT
and could facilitate NO production by the adipocytes in
response to stimulation of β-adrenoceptors.
The results presented show that adipocyte β3-adreno-
ceptor stimulation leads to increased intracellular cAMP
production and KCNQ activation via increased intracellular
calcium leading to release of relaxing factors, one of which
is NO (Figure 7). For the ﬁrst time, we demonstrate that
noradrenaline stimulates release of adipocyte-derived NO.
This NO is a key PDRF and modulates arterial contraction
(Figure 8). These ﬁndings support the targeting of NOS for
the treatment of PVAT dysfunction associated with obesity
and the metabolic syndrome.
Acknowledgements
We thank Dr Elizabeth Cottrell (University of Manchester,
UK) for providing the eNOS/ mice. This work was funded
by a grant from the British Heart Foundation (FS/11/81/
29331).
Author contributions
C.E.B., S.B.W., S.N.S. and A.M.H. designed the experiments
and wrote the paper. C.E.B., S.B.W., S.N.S., N.B. and R.G.A.
performed the experiments and analysed the data. All au-
thors approved the ﬁnal version of the paper. All experiments
were performed in the Heagerty laboratory, University of
Manchester.
Conﬂicts of interest
The authors declare no conﬂicts of interest.
Declaration of transparency and
scientiﬁc rigour
This Declaration acknowledges that this paper adheres to the
principles for transparent reporting and scientiﬁc rigour of
preclinical research recommended by funding agencies, pub-
lishers and other organisations engaged with supporting
research.
References
Aghamohammadzadeh R, Greenstein AS, Yadav R, Jeziorska M, Hama
S, Soltani F et al. (2013). Effects of bariatric surgery on human small
artery function: evidence for reduction in perivascular adipocyte
inﬂammation, and the restoration of normal anticontractile activity
despite persistent obesity. J Am Coll Cardiol 62: 128–135.
Alexander SPH, Striessnig J, Kelly E, Marrion NV, Peters JA, Faccenda
E et al. (2017a). The Concise Guide to PHARMACOLOGY 2017/18:
Voltage-gated ion channels. Br J Pharmacol. 174 (Suppl. 1):
S160–S194.
Alexander SPH, Fabbro D, Kelly E, Marrion NV, Peters JA, Faccenda E
et al. (2017b). The Concise Guide to PHARMACOLOGY 2017/18:
Enzymes. Br J Pharmacol. 174 (Suppl. 1): S272–S359.
Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Marrion NV,
Peters JA et al. (2017c). The Concise Guide to PHARMACOLOGY
2017/18: G protein-coupled receptors. Br J Pharmacol. 174 (Suppl. 1):
S17–S129.
Babu BR, Grifﬁth OW (1998). N5-(1-Imino-3-butenyl)-L-ornithine. A
neuronal isoform selective mechanism-based inactivator of nitric
oxide synthase. J Biol Chem 273: 8882–8889.
Bamshad M, Aoki VT, Adkison MG, Warren WS, Bartness TJ (1998).
Central nervous system origins of the sympathetic nervous system
outﬂow to white adipose tissue. Am J Physiol 275: R291–R299.
Bartness TJ, Liu Y, Shrestha YB, Ryu V (2014). Neural innervation of
white adipose tissue and the control of lipolysis. Front
Neuroendocrinol 35: 473–493.
Briones AM, Daly CJ, Jimenez-Altayo F, Martinez-Revelles S, Gonzalez
JM, McGrath JC et al. (2005). Direct demonstration of β1- and
evidence against β2- and β3-adrenoceptors, in smooth muscle cells of
rat small mesenteric arteries. Br J Pharmacol 146: 679–691.
Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD,
Palin MF (2010). Adiponectin action from head to toe. Endocrine 37:
11–32.
Busse R, Mulsch A (1990). Calcium-dependent nitric-oxide synthesis
in endothelial cytosol is mediated by calmodulin. FEBS Lett 265:
133–136.
Canova NK, Lincova D, Kmonickova E, Kamenikova L, Farghali H
(2006). Nitric oxide production from rat adipocytes is modulated by
β(3)-adrenergic receptor agonists and is involved in a cyclic AMP-
dependent lipolysis in adipocytes. Nitric Oxide-Biol Ch 14: 200–211.
C E Bussey et al.
3696 British Journal of Pharmacology (2018) 175 3685–3698
Chadha PS, Zunke F, Davis AJ, Jepps TA, Linders JT, Schwake M et al.
(2012). Pharmacological dissection of K(v)7.1 channels in systemic
and pulmonary arteries. Br J Pharmacol 166: 1377–1387.
Chambard JM, Ashmore JF (2005). Regulation of the voltage-gated
potassium channel KCNQ4 in the auditory pathway. Pﬂugers Arch
450: 34–44.
Cheng KK, Lam KS, Wang Y, Huang Y, Carling D, Wu D et al. (2007).
Adiponectin-induced endothelial nitric oxide synthase activation
and nitric oxide production are mediated by APPL1 in endothelial
cells. Diabetes 56: 1387–1394.
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz
MA et al. (2018). Experimental design and analysis and their
reporting II: updated and simpliﬁed guidance for authors and peer
reviewers. Br J Pharmacol 175: 987–993.
Fang L, Zhao J, Chen Y, Ma T, Xu G, Tang C et al. (2009). Hydrogen
sulﬁde derived from periadventitial adipose tissue is a vasodilator. J
Hypertens 27: 2174–2185.
Ferguson RE, Carroll HP, Harris A, Maher ER, Selby PJ, Banks RE
(2005). Housekeeping proteins: a preliminary study illustrating some
limitations as useful references in protein expression studies.
Proteomics 5: 566–571.
Flacco N, Segura V, Perez-Aso M, Estrada S, Seller JF, Jimenez-Altayo F
et al. (2013). Different β-adrenoceptor subtypes coupling to cAMP or
NO/cGMP pathways: implications in the relaxant response of rat
conductance and resistance vessels. Br J Pharmacol 169: 413–425.
Foster MT, Bartness TJ (2006). Sympathetic but not sensory
denervation stimulates white adipocyte proliferation. Am J Physiol
Regul Integr Comp Physiol 291: R1,630–R1,637.
Fésüs G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC et al.
(2007). Adiponectin is a novel humoral vasodilator. Cardiovasc Res
75: 719–727.
Gao YJ, Lu C, Su LY, Sharma AM, Lee RM (2007). Modulation of
vascular function by perivascular adipose tissue: the role of
endothelium and hydrogen peroxide. Br J Pharmacol 151: 323–331.
Gao YJ, Zeng ZH, Teoh K, Sharma AM, Abouzahr L, Cybulsky I et al.
(2005). Perivascular adipose tissuemodulates vascular function in the
human internal thoracic artery. J Thorac Cardiovasc Surg 130:
1130–1136.
Garland CJ, Yarova PL, Jimenez-Altayo F, Dora KA (2011). Vascular
hyperpolarization to beta-adrenoceptor agonists evokes spreading
dilatation in rat isolated mesenteric arteries. Br J Pharmacol 164:
913–921.
Ghatta S, Nimmagadda D, Xu X, O’Rourke ST (2006). Large-
conductance, calcium-activated potassium channels: structural and
functional implications. Pharmacol Ther 110: 103–116.
Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O,
Jeziorska M et al. (2009). Local inﬂammation and hypoxia abolish the
protective anticontractile properties of perivascular fat in obese
patients. Circulation 119: 1661–1670.
Gurtler A, Kunz N, Gomolka M, Hornhardt S, Friedl AA, McDonald K
et al. (2013). Stain-free technology as a normalization tool in western
blot analysis. Anal Biochem 433: 105–111.
Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S
et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018:
updates and expansion to encompass the new guide to
IMMUNOPHARMACOLOGY. Nucl Acids Res 46: D1091–D1106.
Hodis J, Vaclavikova R, Farghali H (2011). β-3 agonist-induced
lipolysis and nitric oxide production: relationship to PPARγ
agonist/antagonist and AMP kinase modulation. Gen Physiol
Biophys 30: 90–99.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010).
Animal research: Reporting in vivo experiments: the ARRIVE
guidelines. Br J Pharmacol 160: 1577–1579.
Li R, Andersen I, Aleke J, Golubinskaya V, Gustafsson H, Nilsson H
(2013). Reduced anti-contractile effect of perivascular adipose tissue
on mesenteric small arteries from spontaneously hypertensive rats:
role of Kv7 channels. Eur J Pharmacol 698: 310–315.
Lohn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma
AM (2002). Periadventitial fat releases a vascular relaxing factor.
FASEB J 16: 1057–1063.
Lynch FM, Withers SB, Yao Z, Werner ME, Edwards G, Weston AH
et al. (2013). Perivascular adipose tissue-derived adiponectin activates
BK(Ca) channels to induce anticontractile responses. Am J Physiol
Heart Circ Physiol 304: H786–H795.
McGrath JC, Lilley E (2015). Implementing guidelines on reporting
research using animals (ARRIVE etc.): new requirements for
publication in BJP. Br J Pharmacol 172: 3189–3193.
Minneman KP, Theroux TL, Hollinger S, Han C, Esbenshade TA
(2015). Selectivity of agonists for cloned α1-adrenergic receptor
subtypes. Mol Pharmacol 46: 929–936.
Mulvany MJ, Halpern W (1977). Contractile properties of small
arterial resistance vessels in spontaneously hypertensive and
normotensive rats. Circ Res 41: 19–26.
Ng FL, Davis AJ, Jepps TA, Harhun MI, Yeung SY, Wan A et al. (2011).
Expression and function of the K+ channel KCNQ genes in human
arteries. Br J Pharmacol 162: 42–53.
Nguyen NL, Randall J, Banﬁeld BW, Bartness TJ (2014). Central
sympathetic innervations to visceral and subcutaneous white
adipose tissue. Am J Physiol Regul Integr Comp Physiol 306:
R375–R386.
Ramirez-Ponce MP, Acosta J, Bellido JA, Mateos JC (1998).
Noradrenaline modulates the electrical activity of white adipocytes
by a cAMP-dependent mechanism. J Endocrinol 159: 397–402.
Ramirez-Ponce MP, Mateos JC, Carrion N, Bellido JA (1996). Voltage-
dependent potassium channels in white adipocytes. Biochem
Biophys Res Commun 223: 250–256.
Rebuffe-Scrive M (1991). Neuroregulation of adipose tissue:
molecular and hormonal mechanisms. Int J Obes (Lond) 15 (Suppl. 2):
83–86.
Robidoux J, Kumar N, Daniel KW, Moukdar F, Cyr M, Medvedev AV
et al. (2006). Maximal β3-adrenergic regulation of lipolysis involves
Src and epidermal growth factor receptor-dependent ERK1/2
activation. J Biol Chem 281: 37,794–37,802.
Rooks CR, Penn DM, Kelso E, Bowers RR, Bartness TJ, Harris RB
(2005). Sympathetic denervation does not prevent a reduction in fat
pad size of rats or mice treated with peripherally administered leptin.
Am J Physiol Regul Integr Comp Physiol 289: R92–R102.
Sansbury BE, Cummins TD, Tang Y, Hellmann J, Holden CR,
HarbesonMA et al. (2012). Overexpression of endothelial nitric oxide
synthase prevents diet-induced obesity and regulates adipocyte
phenotype. Circ Res 111: 1176–1189.
Saxton SN, Ryding KE, Aldous RG, Withers SB, Ohanian J, Heagerty
AM (2018). Role of sympathetic nerves and adipocyte catecholamine
uptake in the vasorelaxant function of perivascular adipose tissue.
Arterioscler Thromb Vasc Biol 38: 880–891.
Vasodilator PVAT function in small arteries
British Journal of Pharmacology (2018) 175 3685–3698 3697
Schleifenbaum J, Kohn C, Voblova N, Dubrovska G, Zavarirskaya O,
Gloe Tet al. (2010). Systemic peripheral artery relaxation by KCNQ
channel openers and hydrogen sulﬁde. J Hypertens 28: 1875–1882.
Soeder KJ, Snedden SK, Cao W, Della Rocca GJ, Daniel KW, Luttrell
LM et al. (1999). The β3-adrenergic receptor activates mitogen-
activated protein kinase in adipocytes through a Gi-dependent
mechanism. J Biol Chem 274: 12,017–12,022.
Song CK, Schwartz GJ, Bartness TJ (2009). Anterograde transneuronal
viral tract tracing reveals central sensory circuits from white adipose
tissue. Am J Physiol Regul Integr Comp Physiol 296: R501–R511.
Verdon CP, Burton BA, Prior RL (1995). Sample pretreatment with
nitrate reductase and glucose-6-phosphate-dehydrogenase
quantitatively reduces nitrate while avoiding interference by
NADP(+) when the Griess reaction is used to assay for nitrite. Anal
Biochem 224: 502–508.
Verlohren S, Dubrovska G, Tsang SY, Essin K, Luft FC, Huang Yet al.
(2004). Visceral periadventitial adipose tissue regulates arterial tone
of mesenteric arteries. Hypertension 44: 271–276.
Weston AH, Egner I, Dong Y, Porter EL, Heagerty AM, Edwards G
(2013). Stimulated release of a hyperpolarizing factor (ADHF) from
mesenteric artery perivascular adipose tissue: involvement of
myocyte BKCa channels and adiponectin. Br J Pharmacol 169:
1500–1509.
Withers SB, Agabiti-Rosei C, Livingstone DM, Little MC, Aslam R,
Malik RA et al. (2011). Macrophage activation is responsible for loss of
anticontractile function in inﬂamed perivascular fat. Arterioscler
Thromb Vasc Biol 31: 908–913.
Withers SB, Simpson L, Fattah S, Werner ME, Heagerty AM (2014).
cGMP-dependent protein kinase (PKG) mediates the anticontractile
capacity of perivascular adipose tissue. Cardiovasc Res 101: 130–137.
Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M et al.
(2007). Targeted disruption of AdipoR1 and AdipoR2 causes
abrogation of adiponectin binding and metabolic actions. Nat Med
13: 332–339.
Zavaritskaya O, Zhuravleva N, Schleifenbaum J, Gloe T, Devermann
L, Kluge R et al. (2013). Role of KCNQ channels in skeletal muscle
arteries and periadventitial vascular dysfunction. Hypertension 61:
151–159.
Zhang Y, Matheny M, Zolotukhin S, Tumer N, Scarpace PJ (2002).
Regulation of adiponectin and leptin gene expression in white and
brown adipose tissues: inﬂuence of β3-adrenergic agonists, retinoic
acid, leptin and fasting. Biochim Biophys Acta 1584: 115–122.
C E Bussey et al.
3698 British Journal of Pharmacology (2018) 175 3685–3698
